-
EYPT Dashboard
- Financials
- Filings
-
Holdings
- Transcripts
- ETFs
- Insider
- Institutional
- Shorts
EyePoint Pharmaceuticals (EYPT)
Company Profile
Quarter (USD) | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 79.98 mm | 79.98 mm | 79.98 mm | 79.98 mm | 79.98 mm | 79.98 mm |
Cash burn (monthly) | 3.65 mm | 4.43 mm | 10.92 mm | 9.75 mm | 13.01 mm | 9.46 mm |
Cash used (since last report) | 14.67 mm | 17.83 mm | 43.90 mm | 39.20 mm | 52.32 mm | 38.04 mm |
Cash remaining | 65.31 mm | 62.15 mm | 36.08 mm | 40.78 mm | 27.66 mm | 41.94 mm |
Runway (months of cash) | 17.9 | 14.0 | 3.3 | 4.2 | 2.1 | 4.4 |
13F holders | Current |
---|---|
Total holders | 140 |
Opened positions | 21 |
Closed positions | 37 |
Increased positions | 47 |
Reduced positions | 47 |
13F shares | Current |
---|---|
Total value | 442.81 bn |
Total shares | 67.59 mm |
Total puts | 262.80 k |
Total calls | 176.80 k |
Total put/call ratio | 1.5 |
Largest owners | Shares | Value |
---|---|---|
Cormorant Asset Management | 8.32 mm | $66.52 bn |
Suvretta Capital Management | 5.18 mm | $41.35 bn |
BlackRock | 4.16 mm | $33.20 bn |
BEN Franklin Resources | 4.01 mm | $40.80 bn |
Adage Capital Partners GP, L.L.C. | 3.79 mm | $30.29 bn |
Adage Capital Management | 3.79 mm | $43.45 mm |
Vanguard | 3.05 mm | $24.35 bn |
Therapeutics OcuMension | 3.01 mm | $19.81 mm |
T. Rowe Price | 2.49 mm | $19.91 mm |
EW Healthcare Partners | 2.34 mm | $42.88 mm |
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
8 Jan 25 | Reginald J. Sanders | Stock Options Common Stock | Grant | Acquire A | No | No | 9.11 | 80,000 | 728.80 k | 80,000 |
6 Jan 25 | Jay S. Duker | Common Stock | Payment of exercise | Dispose F | No | No | 8.68 | 6,108 | 53.02 k | 72,706 |
6 Jan 25 | Jay S. Duker | Common Stock | Option exercise | Acquire M | No | No | 0 | 20,794 | 0.00 | 78,814 |
6 Jan 25 | Jay S. Duker | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 20,794 | 0.00 | 39,206 |
5 Jan 25 | Jay S. Duker | Common Stock | Payment of exercise | Dispose F | No | No | 8.26 | 10,007 | 82.66 k | 58,020 |
5 Jan 25 | Jay S. Duker | Common Stock | Option exercise | Acquire M | No | No | 0 | 30,000 | 0.00 | 68,027 |
5 Jan 25 | Jay S. Duker | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 30,000 | 0.00 | 60,000 |
3 Jan 25 | Jay S. Duker | Stock Option Common Stock | Grant | Acquire A | No | No | 8.26 | 390,000 | 3.22 mm | 390,000 |
3 Jan 25 | Jay S. Duker | RSU Common Stock | Grant | Acquire A | No | No | 0 | 195,000 | 0.00 | 228,334 |
3 Jan 25 | Wendy F Dicicco | Stock Option Common Stock | Grant | Acquire A | No | No | 8.26 | 40,000 | 330.40 k | 40,000 |